These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 26993372)

  • 41. A randomized, placebo-controlled trial of sustained-release dextroamphetamine for treatment of methamphetamine addiction.
    Galloway GP; Buscemi R; Coyle JR; Flower K; Siegrist JD; Fiske LA; Baggott MJ; Li L; Polcin D; Chen CY; Mendelson J
    Clin Pharmacol Ther; 2011 Feb; 89(2):276-82. PubMed ID: 21178989
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Executive function moderates naltrexone effects on methamphetamine-induced craving and subjective responses.
    Lim AC; Grodin EN; Green R; Venegas A; Meredith LR; Courtney KE; Moallem NR; Sayegh P; London ED; Ray LA
    Am J Drug Alcohol Abuse; 2020 Sep; 46(5):565-576. PubMed ID: 32343625
    [No Abstract]   [Full Text] [Related]  

  • 43. Bupropion reduces methamphetamine-induced subjective effects and cue-induced craving.
    Newton TF; Roache JD; De La Garza R; Fong T; Wallace CL; Li SH; Elkashef A; Chiang N; Kahn R
    Neuropsychopharmacology; 2006 Jul; 31(7):1537-44. PubMed ID: 16319910
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Subjective and physiological effects of acute intranasal methamphetamine during d-amphetamine maintenance.
    Rush CR; Stoops WW; Lile JA; Glaser PE; Hays LR
    Psychopharmacology (Berl); 2011 Apr; 214(3):665-74. PubMed ID: 21072503
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Subjective and Cardiovascular Effects of Intravenous Methamphetamine during Perindopril Maintenance: A Randomized, Double-Blind, Placebo-Controlled Human Laboratory Study.
    Verrico CD; Haile CN; De La Garza R; Grasing K; Kosten TR; Newton TF
    Int J Neuropsychopharmacol; 2016 Jul; 19(7):. PubMed ID: 27207905
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pharmacological Treatment of Methamphetamine/Amphetamine Dependence: A Systematic Review.
    Siefried KJ; Acheson LS; Lintzeris N; Ezard N
    CNS Drugs; 2020 Apr; 34(4):337-365. PubMed ID: 32185696
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Signal Transduction of Improving Effects of Ibudilast on Methamphetamine Induced Cell Death.
    Tahvilian R; Amini K; Zhaleh H
    Asian Pac J Cancer Prev; 2019 Sep; 20(9):2763-2774. PubMed ID: 31554375
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Mirtazapine to reduce methamphetamine use: a randomized controlled trial.
    Colfax GN; Santos GM; Das M; Santos DM; Matheson T; Gasper J; Shoptaw S; Vittinghoff E
    Arch Gen Psychiatry; 2011 Nov; 68(11):1168-75. PubMed ID: 22065532
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effects of Acute Dance and Aerobic Exercise on Drug Craving and Food Reward in Women with Methamphetamine Dependence.
    Zhou YU; Finlayson G; Liu X; Zhou Q; Liu T; Zhou C
    Med Sci Sports Exerc; 2021 Nov; 53(11):2245-2253. PubMed ID: 34115731
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Ibudilast, a neuroimmune modulator, reduces heavy drinking and alcohol cue-elicited neural activation: a randomized trial.
    Grodin EN; Bujarski S; Towns B; Burnette E; Nieto S; Lim A; Lin J; Miotto K; Gillis A; Irwin MR; Evans C; Ray LA
    Transl Psychiatry; 2021 Jun; 11(1):355. PubMed ID: 34120149
    [TBL] [Abstract][Full Text] [Related]  

  • 51. PG01037, a novel dopamine D3 receptor antagonist, inhibits the effects of methamphetamine in rats.
    Higley AE; Spiller K; Grundt P; Newman AH; Kiefer SW; Xi ZX; Gardner EL
    J Psychopharmacol; 2011 Feb; 25(2):263-73. PubMed ID: 20142301
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A preliminary randomized, double-blind, placebo-controlled study of the safety and efficacy of ondansetron in the treatment of methamphetamine dependence.
    Johnson BA; Ait-Daoud N; Elkashef AM; Smith EV; Kahn R; Vocci F; Li SH; Bloch DA;
    Int J Neuropsychopharmacol; 2008 Feb; 11(1):1-14. PubMed ID: 17470315
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effects of Mirtazapine for Methamphetamine Use Disorder Among Cisgender Men and Transgender Women Who Have Sex With Men: A Placebo-Controlled Randomized Clinical Trial.
    Coffin PO; Santos GM; Hern J; Vittinghoff E; Walker JE; Matheson T; Santos D; Colfax G; Batki SL
    JAMA Psychiatry; 2020 Mar; 77(3):246-255. PubMed ID: 31825466
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Utilizing a Two-stage Design to Investigate the Safety and Potential Efficacy of Monthly Naltrexone Plus Once-daily Bupropion as a Treatment for Methamphetamine Use Disorder.
    Mooney LJ; Hillhouse MP; Thomas C; Ang A; Sharma G; Terry G; Chang L; Walker R; Trivedi M; Croteau D; Sparenborg S; Ling W
    J Addict Med; 2016; 10(4):236-43. PubMed ID: 27379819
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The glial cell modulator ibudilast attenuates neuroinflammation and enhances retinal ganglion cell viability in glaucoma through protein kinase A signaling.
    Cueva Vargas JL; Belforte N; Di Polo A
    Neurobiol Dis; 2016 Sep; 93():156-71. PubMed ID: 27163643
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Placebo-group responders in methamphetamine pharmacotherapy trials: the role of immediate establishment of abstinence.
    Brensilver M; Heinzerling KG; Swanson AN; Shoptaw SJ
    Exp Clin Psychopharmacol; 2012 Oct; 20(5):430-5. PubMed ID: 22867036
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Extended-release methylphenidate for treatment of amphetamine/methamphetamine dependence: a randomized, double-blind, placebo-controlled trial.
    Miles SW; Sheridan J; Russell B; Kydd R; Wheeler A; Walters C; Gamble G; Hardley P; Jensen M; Kuoppasalmi K; Tuomola P; Föhr J; Kuikanmäki O; Vorma H; Salokangas R; Mikkonen A; Kallio M; Kauhanen J; Kiviniemi V; Tiihonen J
    Addiction; 2013 Jul; 108(7):1279-86. PubMed ID: 23297867
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Dopamine D3 receptors as a therapeutic target for methamphetamine dependence.
    Paterson NE; Vocci F; Sevak RJ; Wagreich E; London ED
    Am J Drug Alcohol Abuse; 2014 Jan; 40(1):1-9. PubMed ID: 24359505
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The effects of acute oral naltrexone pretreatment on the abuse potential of intranasal methamphetamine, and the relationship between reward/punishment sensitivity and methamphetamine's effects.
    Jones JD; Mumtaz M; Vadhan NP; Martinez S; Pramanik S; Manubay J; Mogali S; Perez F; Castillo F; Kranzler HR; Comer SD
    Behav Pharmacol; 2022 Jun; 33(4):255-265. PubMed ID: 35438671
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Sustained-release methylphenidate in methamphetamine dependence treatment: a double-blind and placebo-controlled trial.
    Rezaei F; Emami M; Zahed S; Morabbi MJ; Farahzadi M; Akhondzadeh S
    Daru; 2015 Jan; 23(1):2. PubMed ID: 25588930
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.